Table 1. Different complement-modulating drugs listed by activity level along with references of experimental/clinical application.
Substance | Activity | Experimental | Clinical (phase I-III) | |
|---|---|---|---|---|
C1 | C1 inhibitor | Inhibition of C1r and C1s, Kallikrein | ||
scFv (QuVHVL) | Antibody against glomerular heads | (175) | ||
of C1q | ||||
C3 | Compstatin | Peptidic C3 inhibitor | (170) | (169) |
C5 | Eculizumab | Humanized mAb against C5 | (159) | |
Pexelizumab | Humanized mAb against C5 | |||
TNX-558 | Humanized Ab against C5a | (145) | ||
TNX-234 | Humanized Ab against factor D | (145) | ||
Anti-C5a | Ab against C5a | |||
ARC1905 | Aptamer based C5 inhibitor | (174) | ||
C5aR | C5aR inhibitor | C5aR antagonist | ||
Neutrazumab | Ab against C5aR | (145) | ||
PMX-53 (C5aR inhibitor) | Peptidic C5aR antagonist | (168) | ||
JPE-1375, JSM-7717 | Small molecule C5aR antagonists | (145) | ||
CR1 | sCR1/TP10 | Extracellular part of CR1 | ||
sCR1-sLex/TP20 | Soluble CR1 | (148) | ||
Microcept/APT070 | Soluble CR1 | |||
CRegs | CD55 | Recombinant DAF | ||
CD59 inhibitors | Peptides that modulate CD59 expression | (154) | ||
C4BP | Complement regulator | |||
CAB-2/MLN-2222 | Chimera of DAF and MCP | (151) | ||
Serine protease | Nafamostat (FUT-175) | Serine protease inhibitor | (177) | |
Factor D inhibitors | Small molecule serine protease inhibitors | (146) | ||
Others | Hu-Max-CD38; Hu-Max ZP3 | Humanized mAb against CD38 (triggers | (145) | |
complement) | ||||
rhMBL | Recombinant MBL | (171) | ||
Anti-properdin | Ab against properdin | (163) | ||
TA106 | Ab against factor B | (162) | ||
Ofatumumab | Humanized anti-CD20 mAb | (164) | (165) |